Comments

Willow Biosciences

Q: What sector and industry does Willow Biosciences (CANSF) operate in?

Willow Biosciences is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the OTCQB.

CANSFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.056350

~0-0.09%

At close: -

Willow Biosciences (CANSF) Forecast

News Earnings Willow Biosciences (CANSF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Willow Biosciences (OTC:CANSF) Stock Quotes, Forecast and News Summary

Willow Biosciences Stock (OTC: CANSF) stock price, news, charts, stock research, profile.

Open	$0.06
Close	$0.06
Volume / Avg.	1.70K / 69.57K
Day Range	$0.06 - $0.06
52 Wk Range	0.05 - 0.11
Market Cap	$8.13M
P/E Ratio	-
Dividend Yield	-
Exchange	OTC
RSI	0
Short Interest	-
Days to Cover	1.26

Recent News

CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) reported on Monday its financial and operating results for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs. "The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs strategic partnership that includes seven high-value APIs," Dr. Chris Savile, Willow's president and CEO, said. "In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs."

Jelena Martinovic

CBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead

Willow Biosciences Inc., (OTC: CANSF) a frontrunner in biotech innovations for sustainable ingredient production, reported its financial and operational results Tuesday morning for the fourth quarter and fiscal year 2023.

Nicolás Jose Rodriguez

Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology

Biotechnology company Willow Biosciences generated around $1.3m in revenues in 2023, a 60% increase from the previous year. The company has hailed 2023 as a "transformative year," citing the launch of its BioOxi bio-oxidation platform technology as one of its top achievements. The AI-driven selective hydroxylation platform removes multiple chemical steps and reduces the cost of manufacturing target molecules. The technology has enabled Willow to accelerate its path to nearer-term and potentially larger revenue opportunities while reducing operational expenses. The company also engaged in multiple partnerships with innovators and generic pharmaceutical companies, resulting in portfolio expansion and diversification. Willow underwent a restructuring of its corporate and operational framework, including consolidating operations in the San Francisco Bay area and making changes to its leadership team. In 2024, Willow plans to capitalize on the BioOxi technology platform to bring its corticosteroids program to commercial readiness and identify strategic partners for pipeline expansion and acceleration.

Jelena Martinovic

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Open	$0.06
Close	$0.06
Volume / Avg.	1.70K / 69.57K
Day Range	$0.06 - $0.06
52 Wk Range	0.05 - 0.11
Market Cap	$8.13M
P/E Ratio	-
Dividend Yield	-
Exchange	OTC
RSI	0
Short Interest	-
Days to Cover	1.26

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Willow Biosciences (CANSF) stock?

You can purchase shares of Willow Biosciences (OTCQB:CANSF) through any online brokerage.

View our list of the best stock brokerages

Who are Willow Biosciences (CANSF) competitors?

There are no as such competitors for Willow Biosciences.

What is the forecast, or price target, for Willow Biosciences (CANSF) stock?

There is no analysis for Willow Biosciences to provide a consensus price target.

What is the current price for Willow Biosciences (CANSF)?

The stock price for Willow Biosciences (OTCQB: CANSF) is $0.0556 last updated September 6, 2023 at 9:29 AM EDT.

Does Willow Biosciences (CANSF) pay a dividend?

There are no upcoming dividends for Willow Biosciences.

When is Willow Biosciences (OTCQB:CANSF) reporting earnings?

Willow Biosciences does not have any upcoming earnings scheduled.

Is Willow Biosciences (CANSF) going to split?

There is no upcoming split for Willow Biosciences.

What sector and industry does Willow Biosciences (CANSF) operate in?

Willow Biosciences is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the OTCQB.